Tumor Biology

, Volume 36, Issue 6, pp 4671–4679 | Cite as

Relation of glypican-3 and E-cadherin expressions to clinicopathological features and prognosis of mucinous and non-mucinous colorectal adenocarcinoma

  • Abd Al-Rahman Mohammad Foda
  • Mie Ali Mohammad
  • Azza Abdel-Aziz
  • Amira Kamal El-Hawary
Research Article


Glypican-3 (GPC3) is a member of the membrane-bound heparin sulfate proteoglycans. E-cadherin is an adhesive receptor that is believed to act as a tumor suppressor gene. Many studies had investigated E-cadherin expressions in colorectal carcinoma (CRC) while only one study had investigated GPC3 expression in CRC. This study aims to investigate expression of GCP3 and E-cadherin in colorectal mucinous carcinoma (MA) and non-mucinous adenocarcinoma (NMA) using manual tissue microarray technique. Tumor tissue specimens are collected from 75 cases of MC and 75 cases of NMA who underwent radical surgery from Jan 2007 to Jan 2012 at the Gastroenterology Centre, Mansoura University, Egypt. Their clinicopathological parameters and survival data were revised and analyzed using established statistical methodologies. High-density manual tissue microarrays were constructed using modified mechanical pencil tip technique and immunohistochemistry for GPC3 and E-cadherin was done. NMA showed higher expression of GPC3 than MA with no statistically significant relation. NMA showed a significantly higher E-cadherin expression than MA. GPC3 and E-cadherin positivity rates were significantly interrelated in NMA, but not in MA, group. In NMA group, there was no significant relation between either GPC3 or E-cadherin expression and the clinicopathological features. In a univariate analysis, neither GPC3 nor E-cadherin expression showed a significant impact on disease-free survival (DFS) or overall survival (OS). GPC3 and E-cadherin expressions are not independent prognostic factors in CRC. However, expressions of both are significantly interrelated in NMA patients, suggesting an excellent interplay between both, in contrast to MA. Further molecular studies are needed to further explore the relationship between GCP3 and E-cadherin in colorectal carcinogenesis.


Glypican-3 E-cadherin Mucinous Non-mucinous Colorectal adenocarcinoma 


  1. 1.
    Fenoglio-Preiser CM, Noffsinger AE, Stemmermann GN (2008) Epithelial neoplasms of the colon—adenocarcinoma. In: Fenoglio-Preiser CM, Noffsinger AE, Stemmermann GN, editor. Gastrointestinal Pathology: An Atlas and Text, 3rd Edn. Lippincott Williams & Wilkins, pp 955-1016Google Scholar
  2. 2.
    Hamilton SR, Bosman FT, Boffetta P, et al. Tumors of the colon and rectum. In: Bosman FT, Carneiro F, Hruban RH, et al., editors. WHO Classification Of Tumors Of The Digestive System. Lyon: IARCPress; 2010. p. 132–82.Google Scholar
  3. 3.
    Mekenkamp JM, Heesterbeek KJ, Koopman M, et al. Mucinous adenocarcinomas: Poor prognosis in metastatic colorectal cancer. Eur J Cancer. 2012;48:501–9.CrossRefPubMedGoogle Scholar
  4. 4.
    Yamaguchi T, Taniguchi H, Fujita S, Sekine S, Yamamoto S, Akasu T, et al. Clinicopathological characteristics and prognostic factors of advanced colorectal mucinous adenocarcinoma. Histopathology. 2012;61:162–9.CrossRefPubMedGoogle Scholar
  5. 5.
    Foda AA, El-Hawary AK, Abdel-Aziz A. Differential expression of matrix metalloproteinase-13 in mucinous and nonmucinous colorectal carcinomas. Ann Diagn Pathol. 2013;17(4):347–51.CrossRefPubMedGoogle Scholar
  6. 6.
    Foda AA, El-Hawary AK, Abdel Aziz A, Hosni A, Zalata KR, Gado AI. Rare Mucinous colorectal adenocarcinoma: analysis of the epidemiological factors in relation to survival in Egyptian patients. Am J Cancer Epidemiol Prev. 2014;2(1):10–9.Google Scholar
  7. 7.
    Shirakawa H, Suzuki H, Shimomura M, et al. Glypican-3 expression is correlated with poor prognosis in hepatocellular carcinoma. Cancer Sci. 2009;100:1403–7.CrossRefPubMedGoogle Scholar
  8. 8.
    Kandil DH, Cooper K. GPC-3: a novel diagnostic marker for hepatocellular carcinoma and more. Adv Anat Pathol. 2009;16:125–9.CrossRefPubMedGoogle Scholar
  9. 9.
    Shafizadeh N, Ferrell LD, Kakar S. Utility and limitations of GPC-3 expression for the diagnosis of hepatocellular carcinoma at both ends of the differentiation spectrum. Mod Pathol. 2008;21:1011–8.CrossRefPubMedGoogle Scholar
  10. 10.
    Esheba GE, Pate LL, Longacre TA. Oncofetal protein glypican-3 distinguishes yolk sac tumor from clear cell carcinoma of the ovary. Am J Surg Pathol. 2008;32(4):600–7. doi: 10.1097/PAS.0b013e31815a565a.CrossRefPubMedGoogle Scholar
  11. 11.
    Aviel-Ronen S, Lau SK, Pintilie M, et al. GPC-3 is overexpressed in lung squamous cell carcinoma, but not in adenocarcinoma. Mod Pathol. 2008;21:817–25.CrossRefPubMedGoogle Scholar
  12. 12.
    Filmus J. Glypican in growth control and cancer. Glycobiology. 2001;11(3):19R–23.CrossRefPubMedGoogle Scholar
  13. 13.
    Gavard J, Gutkind JS. A Molecular Crosstalk between E-cadherin and EGFR signaling networks. In: Haley JD, Gullick WJ, editors. Cancer drug discovery and development: EGFR signaling networks in cancer therapy 2nd edn. Humana Press: Springer Science; 2008. pp 139-154Google Scholar
  14. 14.
    Capurro MI et al. GPC-3 promotes the growth of hepatocellular carcinoma by stimulating canonical Wnt signaling. Cancer Res. 2005;65(14):6245–54.CrossRefPubMedGoogle Scholar
  15. 15.
    Huang JS et al. Diverse cellular transformation capability of overexpressed genes in human hepatocellular carcinoma. Biochem Biophys Res Commun. 2004;315(4):950–8.CrossRefPubMedGoogle Scholar
  16. 16.
    Rosivatz E, Becker I, Bamba M, Schott C, Diebold J, Mayr D, et al. Neoexpression of N-cadherin in E-cadherin-positive colon cancers. Int J Cancer. 2004;111:711–9.CrossRefPubMedGoogle Scholar
  17. 17.
    Elzagheid A, Algars A, Bendardaf R, et al. E-cadherin expression pattern in primary colorectal carcinomas and their metastases refl ects disease outcome. World J Gastroenterol. 2006;12:4304–9.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Yuan DH, Xie HH, Wang Y, Meng CY, Yang LP, Feng YC, et al. Expression and significance of GPC-3 in colorectal cancer (Abs). Zhonghua Yi Xue Za Zhi. 2008;88(22):1540–2.PubMedGoogle Scholar
  19. 19.
    Shebl AM, Zalata KR, Amin MM, et al. An inexpensive method of small paraffin tissue microarrays using mechanical pencil tips. Diagn Pathol. 2011;6:117–21.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Foda AA. No-cost manual method for preparation of tissue microarrays having high quality comparable to semiautomated methods. Appl Immunohistochem Mol Morphol. 2013;21:271–4.PubMedGoogle Scholar
  21. 21.
    Ou-Yang RJ, Hui P, Yang XJ, Zynger DL. Expression of glypican 3 in placental site trophoblastic tumor. Diagn Pathol. 2010;5:64. doi: 10.1186/1746-1596-5-64.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Khoursheed MA, Mathew TC, Makar RR, et al. Expression of E-cadherin in human colorectal cancer. Surg J R Coll Surg Edinb Irel. 2003;2:86–91.Google Scholar
  23. 23.
    Hahn-stromberg V, Edvardsson H, Bodin L, et al. Disturbed expression of E-cadherin, beta-catenin and tight junction proteins in colon carcinoma is unrelated to growth pattern and genetic polymorphisms. APMIS. 2008;116:253–63.CrossRefPubMedGoogle Scholar
  24. 24.
    Jie D, Zhongmin Z, Guoqing L, et al. Positive expression of LSD1 and negative expression of e-cadherin correlate with metastasis and poor prognosis of colon cancer. Dig Dis Sci. 2013;58:1581–9.CrossRefPubMedGoogle Scholar
  25. 25.
    Tian X, Liu Z, Niu B, et al. E-cadherin/β-catenin complex and the epithelial barrier. J Biomed Biotechnol 2011:567305-567311.Google Scholar
  26. 26.
    Yamauchi N, Watanabe A, Hishinuma M, Ohashi K, Midorikawa Y, et al. The glypican 3 oncofetal protein is a promising diagnostic marker for hepatocellular carcinoma. Mod Pathol. 2005;18:1591–8. doi: 10.1038/modpathol.3800436.PubMedGoogle Scholar
  27. 27.
    Nakatsura T, Nishimura Y. Usefulness of the novel oncofetal antigen glypican-3 for diagnosis of hepatocellular carcinoma and melanoma. BioDrugs. 2005;19(2):71–7.CrossRefPubMedGoogle Scholar
  28. 28.
    Coggin Jr JH. The implications of embryonic gene expression in neoplasia. CRC Crit Rev Oncol Hematol. 1992;5:37–55.CrossRefGoogle Scholar
  29. 29.
    Alshenawy HA, Ali MA. Differential caveolin-1 expression in colon carcinoma and its relation to E-cadherin–β-catenin complex. Ann Diagn Pathol. 2013;17(6):476–82.CrossRefPubMedGoogle Scholar
  30. 30.
    Stanczak A, Stec R, Bodnar L, et al. Prognostic significance of Wnt-1, β-catenin and E-cadherin expression in advanced colorectal carcinoma. Pathol Oncol Res. 2011;17:955–63.CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Fang QX, Lu LZ, Yang B, et al. L1, b-catenin, and E-cadherin expression in patients with colorectal cancer: correlation with clinicopathologic features and its prognostic significance. J Surg Oncol. 2010;102:433–42.CrossRefPubMedGoogle Scholar
  32. 32.
    Elzagheid A, Buhmeida A, Laato M, et al. Loss of E-cadherin expression predicts disease recurrence and shorter survival in colorectal carcinoma. APMIS. 2012;120:539–48.CrossRefPubMedGoogle Scholar
  33. 33.
    El-Bahrawy MA, Poulsom R, Jeffery R, et al. The expression of E-cadherin and catenins in sporadic colorectal carcinoma. Hum Pathol. 2001;32:1216–24.CrossRefPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2015

Authors and Affiliations

  • Abd Al-Rahman Mohammad Foda
    • 1
  • Mie Ali Mohammad
    • 1
  • Azza Abdel-Aziz
    • 1
  • Amira Kamal El-Hawary
    • 1
  1. 1.Pathology Department, Faculty of MedicineMansoura UniversityMansouraEgypt

Personalised recommendations